Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
"We are pleased to have this distribution agreement with Euromed. Theyhave a knowledgeable medical sales force with clinical support in our targetedmarkets, as well as extensive experience in selling temperature modulationproducts," stated Christopher J. Reinhard, Chairman and Chief ExecutiveOfficer of Cardium Therapeutics and InnerCool Therapies. "This new Europeanpartnership, along with our recent distribution agreement for Australia andNew Zealand, are consistent with our strategy of accelerating the growth ofInnerCool's temperature modulation business in an efficient and cost-effectivemanner by establishing relationships with existing specialized internationalsales organizations."
Advertisement
"We are well positioned to successfully initiate marketing and selling theCoolBlue system in Austria, Switzerland and Germany," stated Reinhold Eder,Chief Executive Officer of Euromed, "and we look forward to expanding ourdistribution activities to include InnerCool's next-generation RapidBluesystem when it becomes available later in the year. We believe InnerCool isthe only company positioned to offer a comprehensive portfolio ofbest-in-class temperature modulation solutions for physicians and healthcareproviders in this rapidly expanding therapeutic area."
InnerCool's Surface and Endovascular Temperature Modulation Systems
InnerCool's new CoolBlue(TM) surface temperature modulation system, whichincludes a console and a disposable CoolBlue vest with upper thigh pads, isdesigned to provide a tool for use in less acute patients or in clinicalsettings best suited to prolonged temperature management. InnerCool'sCoolBlue vest and thigh pads wrap the body without requiring any adhesives tostick to the skin and produce cooling rates of around 1 degree C per hour,i.e. similar to those of currently-marketed surface cooling systems andendovascular systems using inflatable balloon-based catheters. InnerCool'sCoolBlue external or surface-based temperature modulation system is designedto cool or warm patients from outside of their bodies and is intended for usein less acute settings such as in-hospital fever management.
InnerCool's next-generation RapidBlue(TM) system for high-performanceendovascular temperature modulation is expected to receive FDA clearance inthe second quarter 2008, and to initially have the same clearance as itscurrent Celsius Control(TM) System. The RapidBlue system includes aprogrammable console with an enhanced user interface and a catheter designedto quickly modulate patient temperature in association with surgery or othermedical procedures. The RapidBlue system powers InnerCool's Accutrol(TM)catheter, which has a flexible metallic temperature control element and abuilt-in temperature feedback sensor to prov
